PDCD1 and melanoma: The PEMDAC trial tested the efficacy of a combination treatment with pembrolizumab, a monoclonal antibody directed against programmed cell death protein 1 (PD-1), with the histone deacetylase inhibitor entinostat, in order to enhance the expression of immune signalling molecules in melanoma cells.